Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Condition:   Influenza Interventions:   Biological: OVX836;   Biological: Quadrivalent seasonal influenza vaccine (Influvac TetraTM) Sponsors:   Osivax S.A.S;   Centre for vaccinology (CEVAC), University of Ghent Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials